TargetMol

L-Ifosfamide

Product Code:
 
TAR-T25723
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T25723-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25723-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25723-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
L-Ifosfamide is nitrogen mustard, a chemotherapeutic antineoplastic, and more precisely an alkylating agent structural analog of cyclophosphamide with respect to which presents some differences regard to the antitumor activity and spectrum.
CAS:
66849-34-1
Formula:
C7H15Cl2N2O2P
Molecular Weight:
261.08
Purity:
0.98
SMILES:
ClCCN[P@@]1(=O)OCCCN1CCCl

References

1. Bisogno G, Jenney M, Bergeron C, Melc?n SG, Ferrari A, Oberlin O, Carli M, Stevens M, Kelsey A, Paoli A, Gaze MN, Martelli H, Devalck C, Merks JH, Ben-Arush M, Glosli H, Chisholm J, Orbach D, Minard-Colin V, De Salvo GL; European paediatric Soft tissue sarcoma Study Group. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 2018 Jun 22. pii: S1470-2045(18)30337-1. doi: 10.1016/S1470-2045(18)30337-1. [Epub ahead of print] PubMed PMID: 29941280. 2. K?lm?n J, Horv?th T, Liktor B, Liktor B. A unique manifestation of Langerhans cell histiocytosis: Diagnostic and therapeutic considerations of atypical cases. Ear Nose Throat J. 2018 Apr-May;97(4-5):E13-E17. PubMed PMID: 29940687. 3. Arndt CAS, Bisogno G, Koscielniak E. Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev. 2018 Jun 19;68:94-101. doi: 10.1016/j.ctrv.2018.06.013. [Epub ahead of print] Review. PubMed PMID: 29940525. 4. Maliszewska O, Plenis A, Ol?dzka I, Kowalski P, Mi?kus N, Bie? E, Krawczyk MA, Adamkiewicz-Dro?ynska E, B?czek T. Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies. J Pharm Biomed Anal. 2018 Jun 19;158:376-385. doi: 10.1016/j.jpba.2018.06.031. [Epub ahead of print] PubMed PMID: 29936377.